证券代码：000915 证券简称：华特达因 公告编号：2025-006 山东华特达因健康股份有限公司 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 3 月 7 日以电子邮件形式发出召开第二次会议的通知，并于 2025 年 3 月 19 日在公司会议室召开会议。会议应参加董事 8 名，实际参加董事 8 名。会议由公司董事长朱效平主持。会议符合有关法律、法规、规章 和《公司章程》的规定。 第十一届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 （一）以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了 《公司 2024 年度总经理工作报告》。 （二）以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了 《关于计提 2024 年度各项资产减值准备的议案》。 2024 年度共计提资产减值准备 4,433.23 万元，其中：根据《企 业会计准则》及公司相关会计政策的规定，基于谨慎性原则，对沂南 华特卧龙学校的固定资产计提减值准备 3,708.47 万元、无形资产计 提 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-010 山东华特达因健康股份有限公司 关于公司2024年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、审议程序 （一）董事会审议情况 2025 年 3 月 19 日，山东华特达因健康股份有限公司（以下简称 "公司"）第十一届董事会第二次会议审议通过了《公司 2024 年度 利润分配预案及资本公积转增股本预案》，本事项尚需提交公司 2024 年度股东大会审议。 （二）监事会审议情况 2025 年 3 月 19 日，公司第十一届监事会第二次会议审议通过了 《公司 2024 年度利润分配预案及资本公积转增股本预案》。监事会 认为：公司 2024 年度利润分配预案符合相关法律法规及《公司章程》 的规定，符合公司实际经营情况。在考虑公司正常经营和长远发展的 前提下，兼顾了股东的即期利益和长远利益，不存在损害公司股东尤 其是中小股东利益的情形，同意将该议案提交公司股东大会审议。 二、2024 年度利润分配预案的基本情况 经致同会计师事务所（特殊普通合伙）审计，公司 2024 年度合 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,134,491,189.49, a decrease of 14.08% compared to CNY 2,484,165,699.48 in 2023[17] - The net profit attributable to shareholders for 2024 was CNY 515,594,983.07, down 11.90% from CNY 585,262,089.70 in the previous year[17] - The net cash flow from operating activities decreased by 20.86% to CNY 929,608,233.71 in 2024, compared to CNY 1,174,684,951.73 in 2023[17] - Basic earnings per share for 2024 were CNY 2.20, a decline of 12.00% from CNY 2.50 in 2023[17] - The total assets at the end of 2024 were CNY 4,930,936,591.73, reflecting a decrease of 5.14% from CNY 5,198,294,479.89 at the end of 2023[17] - The net assets attributable to shareholders decreased by 2.36% to CNY 2,911,651,440.88 at the end of 2024, compared to CNY 2,981,885,170.31 at the end of 2023[17] - The company's weighted average return on equity for 2024 was 17.56%, down from 21.15% in 2023, a decrease of 3.59 percentage points[17] - The company reported a decrease in net profit after deducting non-recurring gains and losses, which was CNY 490,931,743.38 for 2024, down 13.97% from CNY 570,682,128.00 in 2023[17] - The company achieved a revenue of 2.134 billion RMB and a net profit of 516 million RMB in 2024, with a total profit of 1.178 billion RMB[38] - The total profit for 2024 reached CNY 568,790,796.39, an increase from CNY 529,129,734.73 in 2023, representing a growth of approximately 7.5%[192] Cash Flow and Investments - The net cash flow from operating activities decreased by 20.86% to ¥929,608,233.71 compared to ¥1,174,684,951.73 in 2023[52] - Investment activities generated a net cash flow of ¥185,530,507.29, a significant improvement from a negative cash flow of ¥181,296,342.73 in 2023[52] - Cash and cash equivalents increased by ¥24,897,554.50, a decline of 91.61% from ¥296,713,596.47 in 2023[52] - The cash outflow for operating activities in 2024 was CNY 1,965,401,194.92, compared to CNY 1,879,561,464.39 in 2023, an increase of about 4.6%[194] - The cash inflow from investment activities included CNY 2,460,000,000.00 from recovered investments in 2024, up from CNY 2,200,003,500.00 in 2023, reflecting a growth of approximately 11.8%[194] Research and Development - Research and development expenses rose to CNY 101,431,595.50, an increase of 6.93% from CNY 95,593,668.23 in 2023[189] - The R&D department is actively working on developing new probiotic strains, with a target of increasing the active culture count to over 150 billion CFU per serving[30] - The company has applied for 61 patents since 2020, with 45 granted, including 5 PCT patents and 39 invention patents[35] - The company is committed to innovation in drug development, particularly in pediatric medicine, in response to government policies aimed at improving children's healthcare[26] Market Position and Strategy - The company has a leading position in the children's medicine sector, with its product "Yikexin" being a well-known trademark and holding the highest market share in its category[27] - The company is focusing on expanding its children's health product line, including DHA series and various mineral supplements[28] - The implementation of the "three-child policy" is expected to boost demand in the infant market, providing growth opportunities for the company[26] - The company plans to expand its product line by introducing new formulations, including a collagen gel specifically designed for children's skin care, targeting non-chronic wounds[31] - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings in the health supplement industry[31] Governance and Management - The company has maintained a high level of governance, with all board members actively participating in training and adhering to legal regulations, ensuring compliance with governance standards[76] - The company has established a performance evaluation mechanism for senior management, linking compensation to the achievement of operational goals, thereby enhancing motivation[77] - The company is undergoing a significant management reshuffle, with multiple executives, including vice presidents and financial directors, set to change by March 2025[84] - The company has successfully elected new board members and supervisors during its extraordinary general meetings, ensuring a refreshed governance structure[81] Environmental and Social Responsibility - The company invested 3.2 million in environmental protection and paid 0 million in environmental protection tax in 2024[122] - The company has been actively involved in public welfare activities, including the establishment of "Dain Hope Primary School" and participation in various health initiatives[124] - The company has taken measures to reduce carbon emissions and improve environmental processing facilities[122] - The company’s wastewater treatment system operates steadily, ensuring compliance with discharge standards[120] Shareholder Information - The company plans to distribute a cash dividend of CNY 20 per 10 shares to all shareholders based on the total share capital as of December 31, 2024[3] - The total distributable profit for the company is 872,275,430.93 yuan, with cash dividends accounting for 100% of the profit distribution[106] - The controlling shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of the shares, totaling 51,544,340 shares[161] - The company has not reported any significant changes in operational performance metrics in the provided documents, focusing instead on governance and management transitions[84]

证券代码：000915 证券简称：华特达因 公告编号：2025-005 山东华特达因健康股份有限公司 第十一届董事会2025年第二次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 3 月 11 日以电子邮件形式发出召开 2025 年第二次临时会议的通知，并于 2025 年 3 月 12 日以通讯方式召开会议。会议应参加董事 8 名，实际 参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法 律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关于管 理层换届聘任公司副总经理、财务总监的议案"： 第十一届董事会于 2024 年 12 月 30 日经股东大会选举产生，按 照《公司章程》，公司总经理、副总经理等新一届管理层由董事会聘 任。 第十一届董事会第一次会议作出决议，聘任杨杰女士为公司总经 理（职业经理人），任期三年，自 2025 年 1 月 1 日起至 2027 年 12 月 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-004 山东华特达因健康股份有限公司 关于沂南华特卧龙学校诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、有关本案的基本情况 截至本公告披露日，公司及控股子公司暂无其他未裁决的诉讼及 仲裁。 四、本次公告的诉讼对公司本期利润或期后利润的可能影响 根据《企业会计准则》要求，卧龙学校 2023 年度对其资产计提 折旧摊销费用，预计 2024 年度仍需持续承担相关资产的折旧摊销。 五、备查文件 沂南华特卧龙学校于 2024 年 7 月 12 日就上述案件向山东省临沂 市中级人民法院提起上诉。2024 年 10 月 28 日，沂南华特卧龙学校 收到山东省临沂市中级人民法院送达的（2024）鲁 13 民终 7237 号《民 事裁定书》。裁定如下：驳回上诉，维持原裁定。本裁定为终审裁定。 具体情况详见 2024 年 8 月 8 日、2024 年 10 月 29 日刊登于巨潮资讯 网（http://www.cninfo.com.cn）上的《关于沂南华特卧龙学校诉讼 的进展公告》（公告编号：2 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6]. Core Views - The company has strategically refocused on its core business of pediatric pharmaceuticals, leading to significant growth in revenue and profit [3][31]. - The company has successfully divested non-core businesses, enhancing its profitability and operational efficiency [3][31]. - The pediatric drug market is expanding, supported by favorable policies and increasing demand for children's health products [41][42]. Summary by Sections Company Overview - The company has transitioned from a diversified pharmaceutical firm to a leader in pediatric medications, with revenue growing from 170 million RMB in 2006 to 2.43 billion RMB in 2023 [4][19]. - The core product, "Yikexin" (Vitamin AD drops), has maintained a market share of over 60% in its category [19][54]. Financial Performance - From 2020 to 2023, the company's revenue grew at a CAGR of 11%, while net profit grew at a CAGR of 26% [3][31]. - The company has increased its cash dividend payout ratio from 13.6% in 2016 to 80.1% in 2023, with plans for mid-year dividends starting in 2024 [3][38]. Product Development - The company is expanding the target demographic for its core products, with "Yikexin" now marketed for children up to 18 years old [4][54]. - Strategic partnerships, such as with China Resources Sanjiu, are expected to enhance market penetration for key products like "Yidixin" (Vitamin D drops) [4][59]. Market Trends - The pediatric pharmaceutical market is projected to grow, with increasing approvals for children's medications and a focus on vitamin A and D supplementation [41][42]. - The company is well-positioned to capitalize on this growth, with a robust pipeline of new pediatric products planned for annual release [67].

财联社1月17日电，华特达因公告，公司于2025年1月17日收到山东省国有资产投资控股有限公司（公司 控股股东山东华特控股集团有限公司的控股股东）的告知函，山东国投公司正筹划与山东人才发展集团 有限公司进行重组整合事项。 上述事项不涉及公司重大资产重组，不会对公司正常生产经营活动构成重大影响。 该事项不会改变公司控股股东及实际控制人。 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-002 山东华特达因健康股份有限公司 关于公司高级管理人员增持公司股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东华特达因康股份有限公司（以下简称"公司"）收到董事、 总经理杨杰女士、董事会秘书范智胜先生的通知，二人于 2025 年 1 月 10 日通过深圳证券交易所集中竞价交易系统增持了公司股份，现 将有关情况公告如下： 一、增持主体及增持情况 1、增持主体：公司董事、总经理杨杰女士，公司董事会秘书范 智胜先生。 2、增持目的：基于对公司持续稳定发展的信心及对公司长期价 值的认同。 3、资金来源：个人自有资金。 4、增持方式：通过深圳证券交易所交易系统以集中竞价交易方 式增持。 | 姓名 | 职务 | 本次增持前 | | 增持日期 | | | 本次增持数 | 本次增持均 | 本次增持后持股 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 持股数量 （股） | | | | | 量（股） | ...

证券代码：000915 证券简称：华特达因 公告编号：2025-001 山东华特达因健康股份有限公司 第十一届董事会 2025 年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 1 月 3 日以电子邮件形式发出召开第十一届董事会 2025 年第一次临时会 议的通知，并于 2025 年 1 月 6 日以通讯方式召开。会议由董事长朱 效平先生主持，应参加董事 8 名，实际参加董事 8 名。会议符合有关 法律、法规、规章和《公司章程》的规定。 经参会董事签字并加盖董事会印章的董事会决议。 特此公告 山东华特达因健康股份有限公司董事会 2025 年 1 月 7 日 会议以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关 于公司子公司达因药业购置选丸机的议案"：同意控股子公司山东达 因海洋生物制药股份有限公司以自有资金购置 4 台选丸机，总购置价 约 2400 万元人民币。 三、备查文件 ...

（二）以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了 "关于第十一届董事会各专业委员会组成人员的议案"： 证券代码：000915 证券简称：华特达因 公告编号：2024-048 山东华特达因健康股份有限公司 第十一届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司于 2024 年 12 月 30 日召开临时 股东大会，选举产生了公司第十一届董事会。董事会于 2024 年 12 月 30 日在公司会议室召开了第一次会议。会议应参加董事 8 名，实际 参加董事 8 名。会议由现场半数以上董事推选董事朱效平先生主持。 会议符合有关法律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 （一）以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关 于选举公司董事长的议案"：选举朱效平为公司董事长，任期三年。 根据董事长提名，第十届董事会各专业委员会组成人员如下： 1、战略委员会： 主任委员：朱效平，委员：杨杰、张志元、杜宁、刘成安 2、提名委员会： 主任委员： ...